Skip to main content
. Author manuscript; available in PMC: 2014 Feb 24.
Published in final edited form as: Clin Cancer Res. 2012 Mar 8;18(9):2545–2557. doi: 10.1158/1078-0432.CCR-11-2592

Figure 4. YM155, a small molecule survivin inhibitor, inhibits MPNST cell growth in vitro.

Figure 4

A. WB analyses confirm that YM155 induces a dose- (in the nM range) and treatment time-dependent decrease in survivin expression in MPNST cell lines. No decrease in the expression of the IAP proteins XIAP or cIAP1 was observed in response to YM155; B. MTS assays demonstrating a marked YM155 dose-dependent decrease in MPNST cell growth after 48 and 96h of treatment. A correlation between YM155 sensitivity and cell line growth rate was observed. Of note, a less pronounced effect was demonstrated in MPNST642 cells -- amongst the human MPNST cell lines tested, this cell line exhibits the slowest growth and lowest survivin expression; C. YM155 (pretreatment and continuous treatment) significantly inhibits the colony forming capacity of MPNST cells (graphs represent at least three independent experiments); D. YM155 significantly inhibits the anchorage independent growth of MPNST cells (graphs represent at least three independent experiments). [* denotes statistically significant effects (p<0.05)]